Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16585100 | 0.88 | MEN1 (0.50) | FFAR1ALDH1A1KMT2AMEN1CYP2C19 | |
| SCHEMBL17985242 | 0.88 | MEN1 (0.50) | FFAR1ALDH1A1KMT2AMEN1CYP2C19 | |
| SCHEMBL16585271 | 0.88 | MEN1 (0.50) | FFAR1ALDH1A1KMT2AMEN1CYP2C19 | |
| SCHEMBL1586594 | 0.83 | ALDH1A1 (0.41) | TSHRALDH1A1KMT2AMEN1SLC9A1 | |
| SCHEMBL6130264 | 0.83 | ALDH1A1 (0.41) | TSHRALDH1A1KMT2AMEN1SLC9A1 | |
| SCHEMBL15938770 | 0.80 | HTR2A (0.50) | FFAR1TSHRALDH1A1KMOKMT2A | |
| SCHEMBL7000314 | 0.79 | SLC9A1 (0.62) | FFAR1TSHRKMOKMT2AMEN1 | |
| SCHEMBL3422742 | 0.79 | SLC9A1 (0.62) | FFAR1TSHRKMOKMT2AMEN1 | |
| SCHEMBL12875725 | 0.79 | SLC9A1 (0.62) | FFAR1TSHRKMOKMT2AMEN1 | |
| SCHEMBL28820132 | 0.79 | HTR2C (0.39) | ALDH1A1KMT2AMEN1POLBSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | LPAR5, LPAR2, LPAR1 | FFAR1 85/4885TSHR 2391/4885ALDH1A1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.